Technical Analysis for BBIO - BridgeBio Pharma, Inc.

Grade Last Price % Change Price Change
D 14.51 1.75% 0.25
BBIO closed up 1.86 percent on Friday, June 2, 2023, on 43 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Up

Date Alert Name Type % Chg
20 DMA Support Bullish 1.75%
Bollinger Band Squeeze Range Contraction 1.75%
NR7 Range Contraction 1.75%
Up 3 Days in a Row Strength 1.75%
Crossed Above 20 DMA Bullish 3.64%
Bollinger Band Squeeze Range Contraction 3.64%
20 DMA Resistance Bearish 5.76%
MACD Bullish Signal Line Cross Bullish 5.76%
Bollinger Band Squeeze Range Contraction 5.76%
20 DMA Resistance Bearish 7.16%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakout 3 minutes ago
Up 2% 3 minutes ago
Upper Bollinger Band Resistance 3 minutes ago
Rose Above Previous Day's High about 2 hours ago
Up 1% about 2 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

BridgeBio Pharma, Inc. Description

BridgeBio Pharma, Inc. engages in developing transformative medicines to treat patients who suffer from mendelian diseases. Its pipeline of 15 development programs includes product candidates from early discovery to late-stage development. The firm develops BBP-265, an oral small molecule transthyretin for the treatment of TTR amyloidosis, including cardiomyopathy and polyneuropathy manifestations; infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor for the treatment of FGFR-driven cancers and in preclinical development for the treatment of achondroplasia; and BBP-631, a preclinical adeno-associated virus, gene transfer product candidate, for the treatment of congenital adrenal hyperplasia caused by 21OHD. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly and Neil Kumar on May 17, 2019 and is headquartered in Palo Alto, CA.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Clinical Development Organ Systems Tyrosine Kinase Receptors Protein Kinase Inhibitor Tyrosine Kinase Amyloid Amyloidosis Fibroblast Growth Factor Receptor Hyperplasia Myopathy Cardiomyopathy Transthyretin Achondroplasia Congenital Adrenal Hyperplasia Familial Amyloid Polyneuropathy Polyneuropathy TTR Amyloidosis

Is BBIO a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 19.945
52 Week Low 5.74
Average Volume 2,138,563
200-Day Moving Average 11.47
50-Day Moving Average 14.67
20-Day Moving Average 13.84
10-Day Moving Average 13.72
Average True Range 0.82
RSI (14) 52.61
ADX 8.64
+DI 21.40
-DI 17.17
Chandelier Exit (Long, 3 ATRs) 12.51
Chandelier Exit (Short, 3 ATRs) 15.20
Upper Bollinger Bands 14.52
Lower Bollinger Band 13.16
Percent B (%b) 0.81
BandWidth 9.82
MACD Line -0.16
MACD Signal Line -0.23
MACD Histogram 0.0683
Fundamentals Value
Market Cap 1.75 Billion
Num Shares 123 Million
EPS -10.90
Price-to-Earnings (P/E) Ratio -1.31
Price-to-Sales 259.96
Price-to-Book 36.28
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 15.10
Resistance 3 (R3) 15.02 14.66 14.96
Resistance 2 (R2) 14.66 14.44 14.70 14.91
Resistance 1 (R1) 14.46 14.31 14.56 14.54 14.87
Pivot Point 14.10 14.10 14.15 14.14 14.10
Support 1 (S1) 13.90 13.88 14.00 13.98 13.65
Support 2 (S2) 13.54 13.75 13.58 13.61
Support 3 (S3) 13.34 13.54 13.56
Support 4 (S4) 13.42